Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating disease caused by reactivation of JC (John Cunningham) polyomavirus (JCV) from latent infection in patients with impaired immune systems. No specific treatment is available, but restoration of immune system function through combination antiretroviral treatment (cART) in human immunodeficiency virus (HIV)-infected patients or withdrawal of immunosuppressive or immunomodulant drugs in those with iatrogenic immunodeficiencies may lead to disease remission or improved survival [1, 2] .
JCV-DNA detection in the cerebrospinal fluid (CSF) is diagnostic of PML in patients with consistent clinical and radiological pictures [3] [4] [5] , with a negative prognostic value if high levels are present in HIV-infected, cART-untreated patients [6] . Approximately one quarter of healthy patients shed JCV in urine [7] , likely as a result of persistent virus replication in the urinary tract, but with no diagnostic or prognostic value for PML. Detection of the JCV genome in plasma and peripheral blood mononuclear cells (PBMCs) has been reported in a variable proportion of patients with PML [8, 9] and also of immunocompetent and immunocompromised patients without PML [8] [9] [10] [11] [12] [13] [14] [15] ; however, its diagnostic and prognostic significance remains uncertain.
Our objectives in this study were to evaluate the diagnostic value of plasma JCV-DNA in PML patients and the correlations between its levels and JCV-DNA levels in other biological samples, clinical and laboratory variables, and survival.
and neurology departments at San Raffaele Hospital, Milano, the San Patrignano Medical Center, Rimini, or the Mondino National Institute of Neurology, Pavia, and healthy volunteers. All biological samples were collected between 1993 and 2013 for either diagnostic purposes or as part of research protocols.
PML was diagnosed as definite in the presence of JCV-DNA in CSF along with consistent clinicoradiological picture, or typical neuropathological findings at post-mortem examination, or as possible in patients with consistent clinical and neuroradiological findings alone [4, 5] .
Demographic, clinical, and laboratory data were extracted from hard copy records and electronic databases; magnetic resonance (MR) images were reviewed by a neuroradiologist (S. G.). We defined "progressors" as PML patients who either died or showed progressive deterioration at last evaluation and "survivors" as those with clinical, radiological, and, in cases with available follow-up samples, virological (ie, clearance of JCV-DNA from CSF) remission. Immune reconstitution inflammatory syndrome (IRIS) was defined as worsening of neurological symptoms associated with evidence of contrast enhancement at magnetic resonance imaging (MRI) following cART initiation or reversion of immune suppression [4] .
All patients and controls who were still alive at the time of the study gave written informed consent. The ethics committee gave permission for the use of samples and clinical information from patients who were deceased.
Samples and Laboratory Analyses
EDTA blood samples were either separated using the FicollPaque gradient or centrifuged at 1500 g for 10 minutes. Plasma and uncentrifuged CSF samples and urine supernatants were aliquoted and stored at −80°C until analysis. PBMC aliquots were stored as snap-frozen pellets.
Nucleic acids were extracted from 200 µL of plasma, CSF or urine, or frozen PBMCs and eluted in a final volume of 100 µL. Nucleic acid amplification was performed using real-time polymerase chain reaction as described [6] . The lower detection limit of the assay was 100 copy numbers/mL, with no differences depending on the type of fluid. For statistical purposes, undetectable JCV-DNA was recorded as being equal to this value.
JCV Viral Protein (VP)1-specific immunoglobulin G titers were assessed in 79 PML patients. Plasma samples were diluted 1:200 and tested with an in-house enzyme-linked immunosorbent assay using the JCV Mad-1 viral-like particle as antigen (kindly provided by Biogen) [16] . All samples were analyzed in duplicate; the cutoff value of the assay was defined at an optical density value of 0.3.
Statistical Analyses
Data are presented as absolute number (%) and median (interquartile range [IQR] ). Base-10 logarithmic transformations were applied to JCV-DNA and HIV-RNA copy values for analysis. The Kruskal-Wallis and 2-sided Fisher exact tests were used for comparison between groups. Associations between plasma JCV-DNA (detection and levels) and other variables were assessed with stepwise logistic regression models, and correlations between continuous variables were assessed with the Spearman correlation coefficient. Time of follow-up was measured from sampling date until date of death or last observation. In the univariate analysis, the Cox proportional hazards regression model was used to evaluate associations between survival and candidate predictors. The distribution of survival times was estimated using the Kaplan-Meier method; survival curves in patient subgroups were compared using the log-rank test. In the multivariate survival analysis, we incorporated a time-updated effect of cART initiation as a time-updated covariate in the Cox proportional hazards model to assess the effect of not being vs being on cART during follow-up. Interaction terms between being on cART and being JCV-plasma positive were used to assess the hazard difference for PML progression among cART-treated and untreated patients with detectable and undetectable JCV-DNA in plasma.
RESULTS

PML Patient Characteristics
We evaluated 103 patients with PML (with 103 plasma, 103 CSF, and 51 urine samples available), including 79 with HIV infection and 24 with other causes of immunosuppression, and 144 control patients without PML, including 49 HIV-positive patients (49 plasma, 11 CSF, and 12 urine samples) and 95 HIVnegative patients (95 plasma and 87 urine samples; 19 kidney transplant recipients, 41 natalizumab-treated MS patients, and 35 healthy volunteers). MR images, performed a median of 3 days before sampling (IQR, −14 to 3), were reviewed for 95 of the 103 PML patients.
Among patients with HIV-related PML, 56 received cART that consisted of a combination of at least 3 active drugs, including 41 on cART at the time of sampling and 15 who started cART afterward (Table 1) . Forty-three patients received 1 or more PML-directed treatments before and/or after sampling, including cidofovir (n = 24), mefloquine (n = 10), mirtazapine (n = 7), cytarabine (n = 6), or interleukin-7 (n = 2). Nine of 95 patients with complete data available received high-dose intravenous (HDIV) steroid therapy for suspected or confirmed IRIS (1 g methylprednisolone for 3-5 days, with or without subsequent tapering).
Compared to HIV-negative PML patients, HIV-positive patients were younger, had fewer malignancies but more severe infections, and had lower CD4+ cell counts ( Table 1) . None of the variables examined was significantly different between cARTtreated and untreated patients at the time of sampling, except for 6 cases of IRIS that had all occurred in cART-treated patients.
JCV-DNA Detection in Plasma, CSF, and Urine JCV-DNA was recovered from plasma for 49 of 103 (48%) patients with PML, more frequently in HIV-negative compared to HIV-positive patients (83% vs 37%, P < .0001), and in 4 of 144 (3%) control patients, all with HIV infection (Figure 1 ). Diagnostic sensitivity and specificity of JCV-DNA in plasma were 48% and 97% in the whole cohort, 83% and 100% in HIVnegative patients, and 37% and 92% in HIV-positive patients. JCV-DNA plasma levels in HIV-negative patients were higher than in HIV-positive patients (P < .0001).
JCV-DNA was found in CSF for 87 of 103 (84%) PML patients, again, more frequently in HIV-negative than in HIVpositive patients (100% vs 80%, P = .019), but in none of the 11 control patients with HIV infection (Figure 1 ). Because CSF JCV-DNA detection was a criterion for PML diagnosis, its sensitivity and specificity were not calculated. Four of 16 HIVinfected patients with negative JCV-DNA in CSF (25%) had detectable JCV-DNA in plasma (range, 2.22-3.15 log 10 c/mL), including 2 patients with definite diagnosis, either achieved at post-mortem examination or by JCV-DNA detection in a subsequent CSF test. CSF levels were lower than in plasma for 13 of 103 patients (13%). CSF JCV-DNA levels were higher in HIVnegative than in HIV-positive patients (P = .017).
JCV-DNA was found in urine for 30 of 51 (59%) PML patients, including 46% HIV-negative and 63% HIV-positive patients, and in 27 of 99 (27%) control patients, more frequently in HIV-positive than in HIV-negative controls (58% vs 23%, P = .016; Figure 1 ). Diagnostic sensitivity and specificity of JCV-DNA detection in urine were 59% and 73% in the whole group, 46% and 77% in HIV-negative patients, and 63% and 42% in HIV-positive patients. PBMCs were available from 20 patients with HIV-related PML from the same blood samples used for plasma analysis. JCV-DNA was undetectable in PBMCs in all the patients, including 9 with plasma samples that were JCV-DNA positive (median plasma JCV-DNA, 2.00 c/mL; range, 2.00-3.66 c/mL).
Variables Associated with Plasma JCV-DNA in PML Patients
JCV-DNA was more likely to be detected in plasma of HIVnegative patients; in patients with higher CSF JCV-DNA levels, with the probability of detection increasing by more than 2-fold for each 1 log-base 10 increase of JCV-DNA copies/mL in CSF; and in patients who had received HDIV steroids before sampling (Table 2 ). Higher CSF JCV-DNA and previous steroid use were also associated with JCV-DNA detection in plasma in HIV-positive, but not in HIV-negative, patients. By multivariable analysis, the presence of JCV-DNA in plasma remained independently associated only with no HIV infection (odds ratio [OR], 9.52; 95% confidence interval [CI], 2.41-37.53; P = .001) and higher CSF JCV-DNA level (OR 2.182, 95% CI 1.47-3.23, P < .0001). Regression analysis confirmed a positive linear correlation between plasma and CSF JCV-DNA levels in HIV-positive, but not in HIV-negative, PML patients ( Figure 2 ).
Variables Associated with PML Progression
Overall, median patient follow-up was 1293 days (IQR, 472-2313; range, 14-5607) from onset of PML symptoms and 1224 days (IQR, 424-2122; range, 0-5594) from sampling. Seventy-five of 103 patients (73%) were classified as progressors; 64 died and 11 were deteriorating at last evaluation, including 17/24 (71%) HIV-negative and 58/79 (73%) HIV-positive patients. Among HIV-positive patients, PML progressed in all of the 23 patients who never received cART and in 38 of 56 (68%) cART-treated patients.
Plasma JCV-DNA levels were significant predictors of progression in both HIV-negative and HIV-positive patients (Table 3) . Additional predictors of PML progression were plasma JCV-DNA detectability and presence of malignancies in HIV-negative patients and, in HIV-positive patients, higher levels of CSF JCV-DNA, PML lesions in the brain stem, and absence of contrast enhancement at MRI (Table 3) . By survival analysis, plasma JCV-DNA detectability was confirmed to be a strong predictor of progression in HIV-negative patients and, among HIV-positive patients, only in those who were receiving cART ( Figure 3) . In contrast, a CSF JCV-DNA level above a cutoff value of 3.71 log copies/mL (ie, the overall median value of CSF JCV-DNA) was associated with worse outcome in both cART-untreated and cART-treated HIV-positive, but not in HIV-negative, patients ( Figure 3 ). This finding was further supported by a multivariable Cox model that showed an increased risk of progression in cART-treated patients with increasing plasma JCV-DNA levels by more than 2-fold for each log 10 unit increase in JCV-DNA copies/mL (Table 4) , thereby suggesting that this parameter may identify a group of patients with poorer outcome despite cART. 
DISCUSSION
Here, we show that identification of JCV-DNA in plasma has low sensitivity (48%) but high specificity (97%) in PML patients, with the highest values in HIV-negative patients (83% and 100%, respectively). Of note, we recovered JCV-DNA in plasma from 4 of 16 PML patients who were negative for JCV-DNA in CSF. Because undetectable CSF JCV-DNA does not rule out PML diagnosis due to diagnostic sensitivity of only 70%-80% of JCV-DNA detection in the CSF [3] [4] [5] , testing for plasma JCV-DNA might help corroborate a presumptive PML diagnosis when CSF examination is inconclusive or when lumbar puncture is contraindicated. Studies on smaller case series reported similar frequencies of plasma detection in patients with PML [8, 9, 12] . Also in patients at risk without PML, for example, HIV-infected, transplanted, or with MS on natalizumab, the reported rates of detection were similarly low or lower in the majority of the studies, with detection of low copy numbers in positive patients [12] [13] [14] 17] . Higher frequencies were reported in old studies of HIVpositive patients, presumably in association with a high degree of immune suppression [8, 9, 18] or when ultrasensitive techniques in repeat samples were used [15] . However, the presence of JCV-DNA in plasma never predicted subsequent onset of PML.
We found that plasma JCV-DNA levels correlated with CSF JCV-DNA levels, as predictable by the physiological exchanges between blood and CSF compartments. In line with these finding, we previously described similarly mutated sequences of VP1, the major JCV capsid antigen, in paired plasma and CSF samples, both differing from urine-derived wild-type sequences [19] . Identical rearranged noncoding control region (NCCR) sequences were also found in blood and CSF drawn simultaneously from the same patients [20] [21] [22] . Because PML is caused by JCV replication in brain cells upon acquisition of VP1 mutations [23] and NCCR rearrangements, it is conceivable that JCV-DNA in plasma corresponds to the viral DNA that is shed in the CSF by productively infected brain cells. However, we detected JCV-DNA in the plasma, but not in the CSF, of 4 patients, and JCV-DNA levels that were higher in plasma than in CSF in 9 additional PML patients, for a total of 13 patients (13%) with higher JCV-DNA replication in plasma than in CSF. We reviewed plasma and CSF sequences available for VP1 [19] and NCCR (unpublished data) from 2 of these cases and from other patients of the present study. Of note, plasma from the first patient contained minority VP1 variants that were not present in CSF, which is different from what we observed in the second patient and in 7 patients with plasma JCV-DNA that was lower than in CSF, with the same variants in the 2 compartments [19] . In turn, NCCR sequencing revealed rearrangement patterns that were different between plasma and CSF in the second patient, but not in the first patient or in the 9 patients with plasma JCV-DNA that was lower than in CSF (data not shown). These observations suggest that in a minority of cases, JCV might spread to and replicate further in peripheral tissues in addition to the intrathecal replication. JCV antigens have been retrieved from extracerebral tissues, including the urinary tract, PBMCs, and bone marrow [1, 10, 24] . However, the fact that only wild-type virus, that is, without VP1 mutations and NCCR rearrangements, is found in urine [19] [20] [21] [22] seems to rule out the urinary tract as a possible source of plasma JCV-DNA in PML. On the other hand, we did not find JCV-DNA in PBMCs of our PML patients, and so this study provides no clues as to a specific extracerebral source of JCV-DNA in PML.
We detected plasma JCV-DNA in HIV-negative PML patients more frequently and at higher levels than in HIV-positive patients. The former were older and had higher CD4+ cell counts than HIV-infected patients; it is possible that older age, with the accompanying fading immune system function and/or different forms of immunosuppression, might have favored JCV replication in the intrathecal compartment and thus spread to the blood. Plasma JCV-DNA was also detected more frequently and at higher levels in patients who had received HDIV steroids prior to sampling. Studies in MS patients without PML showed decreased JCV-specific T-cell responses following administration of HDIV steroids [25, 26] . Of note, steroids can exert a direct proliferative effect on BK polyomavirus in vitro [27, 28] ; by analogy, a similar effect can also be hypothesized on JCV. Longitudinal analysis of plasma samples drawn before and after steroid administration might help clarify their effect on JCV replication.
Of interest for the clinical management of PML, we found that both presence of plasma JCV-DNA (in HIV-negative and cART-treated, HIV-positive patients) and high plasma levels (in all PML groups) were strongly predictive biomarkers of disease progression. Consistent with previous reports, poor outcome was also associated with higher levels of JCV-DNA in CSF [6, 18, [29] [30] [31] ; the presence of PML lesions in the brain stem; and no contrast enhancement at MRI, which is a sign of immune recovery [32] , and also with severity of underlying conditions such as malignancies in HIV-negative patients. The association of plasma JCV-DNA detection with survival has been addressed in 2 previous studies. Similar to our findings, there was no association with survival among HIV-infected patients in a study in the pre-cART era [18] . A subsequent survey showed no prognostic value of blood JCV-DNA detection; however, no distinctions between plasma and PBMCs and between HIV-positive and HIV-negative patients were described [12] . Of note, in the present study, the presence of JCV-DNA in plasma also identified a group of HIV-positive patients who progressed despite being on cART and at a similar rate as that of the cART-untreated patients. Thus, JCV-DNA detection in plasma seems to be a negative prognostic factor even in patients on cART.
Why higher plasma levels are associated with disease progression is unclear, and it can only be matter of speculation. Because, in most of the cases, the plasma virus seems to originate from central nervous system (CNS) virus, this association might be explained, in part, by the correlation with high CSF viral load, which likely reflects poor immune control and higher CNS replication. In addition, extended brain damage may increase the permeability of the brain barriers, with further release of virus to the blood. On the other hand, there seem to be cases where plasma virus originates from peripheral sites and where JCV replicates in plasma independently from the CNS. In these cases, high plasma levels simply represent a proxy for more aggressive brain disease due to poor immune control.
Finally, and although this was not addressed in this study, it is reasonable to assume and there is preliminary evidence [33] to show that quantification of JCV-DNA in plasma samples collected longitudinally may represent a reliable and simple approach for virological monitoring of PML progression over time, which is similar and in addition to JCV-DNA quantification in CSF [4] .
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